Sound Income Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sound Income Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26	Closed	-$1.49K	–	714
2026 Q1	$1.49K	Hold	26	–	–	﹤0.01%	2221
2025 Q4	$1.42K	Buy	+26	New	+$1.42K	﹤0.01%	2221
2020 Q3	–	Sell	-24	Closed	-$3K	–	841
2020 Q2	$3K	Buy	+24	New	+$2.38K	﹤0.01%	566

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Sound Income Strategies's BMRN Position: Q2 2026 in Review

Sound Income Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 26 shares — an estimated $1.49K sold.

Sound Income Strategies first reported a position in BMRN in Q2 2020 and held it in 3 quarters. The position peaked at $3K in Q2 2020. 173 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sound Income Strategies reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sound Income Strategies sold 26 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.49K.
Sound Income Strategies first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 3 quarters.
Sound Income Strategies's BioMarin Pharmaceuticals position peaked at $3K in Q2 2020.
173 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.